Tall Cell Variant Thyroid Gland Papillary Carcinoma

Tall Cell Variant Thyroid Gland Papillary Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

3 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02973997	Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)	completed	Phase 2	57	Academic and Community Cancer Research UnitedOTHER	1	Aug 29, 2025	clinicaltrials
NCT01811212	Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer	completed	Phase 2	25	National Cancer Institute (NCI)NIH	1	Apr 3, 2018	clinicaltrials